
Eris Lifesciences reported its Q3 FY25 financial results, showcasing strong revenue growth but a decline in net profit due to higher expenses. The company’s revenue from operations surged to ₹727.45 crore, marking a 49.6% year-on-year (YoY) growth compared to ₹486.30 crore in Q3 FY24. The total income stood at ₹731.67 crore, up from ₹490.50 crore YoY.
However, despite the impressive top-line growth, the company’s net profit fell by 14.3% YoY to ₹86.93 crore from ₹101.46 crore in the same period last year. The decline in profitability is attributed to a significant increase in expenses.
Key Financial Highlights:
- Revenue from Operations: ₹727.45 crore, up 49.6% YoY from ₹486.30 crore.
- Total Income: ₹731.67 crore versus ₹490.50 crore YoY.
- Net Profit: ₹86.93 crore compared to ₹101.46 crore, down 14.3% YoY.
- Profit before Tax: ₹116.16 crore versus ₹115.87 crore in Q3 FY24.
- Total Expenses: ₹615.51 crore, up from ₹374.63 crore YoY.
Breakdown of Expenses:
- Higher material costs and operational expenses contributed to the rise in total expenses, which increased by over 64% YoY. Employee benefits and finance costs also saw a significant jump.
The company’s profit before tax stood at ₹116.16 crore, slightly higher than the ₹115.87 crore recorded in the corresponding period last year. However, higher tax expenses further compressed the net profit.
This quarter’s performance highlights the company’s ability to grow revenues rapidly but emphasizes the need for cost control to protect profit margins in the upcoming quarters.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.